Atossa Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

Atossa Therapeutics

10/11/2026 14:31

Atossa Therapeutics Inc ATOS.OQ reported a quarterly adjusted loss of 56 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-1.05.  The mean expectation of three analysts for the quarter was for a loss of 89 cents per share. Wall Street expected results to range from $-1.15 to -74 cents per share.
Reported revenue was zero​; analysts expected zero. 
Atossa Therapeutics Inc's reported EPS for the quarter was a loss of 56 cents​.
The company reported a quarterly loss of $5.64 million.
Atossa Therapeutics Inc shares had risen by 9.2% this quarter and lost 75.9% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 18% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Atossa Therapeutics Inc is $22.00, about 90.3% above its last closing price of $2.13
This summary was machine generated from LSEG data November 10 at 02:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Sep. 30 2026 
-0.89
-0.56
Beat
Jun. 30 2026 
-1.02
-0.95
Beat
Mar. 31 2026 
-6.12
-1.11
Beat
Dec. 31 2025 
-1.14
-3.08
Missed